Novo Nordisk Skeptic Finally Upgrades Stock
Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...
Hosted on MSN2mon
A next-gen Ozempic falls short in a drug trial — and Novo Nordisk stock plunges 20%The logo of Danish pharmaceutical company Novo Nordisk is pictured at their headquarters ... saw their stocks rise 5% and 3%, respectively, on Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results